Three trials to assess ARD-101 including for refractory weight gain post-bariatric surgeryEnrolment has begun in three Phase 2 studies of ARD-101, a first-in-class small molecule bitter taste receptor (TAS2R) pan-agonist. Two...
LSG and RYGB-induced upregulation of apoA-IV is beneficial for insulin secretion and energy expenditure5 days ago
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity5 days ago